Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GALACTIC-1 - A Randomized, Double-blind, Multicentre, Parallel, Placebo-controlled Phase 2b Study in Subjects With Idiopathic Pulmonary Fibrosis Investigating the Efficacy and Safety of TD139, an Inhaled Galectin-3 Inhibitor Administered Via Dry Powder Inhaler Over 52 Weeks

Trial Profile

GALACTIC-1 - A Randomized, Double-blind, Multicentre, Parallel, Placebo-controlled Phase 2b Study in Subjects With Idiopathic Pulmonary Fibrosis Investigating the Efficacy and Safety of TD139, an Inhaled Galectin-3 Inhibitor Administered Via Dry Powder Inhaler Over 52 Weeks

Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 05 Feb 2019

At a glance

  • Drugs TD 139 (Primary) ; Nintedanib; Pirfenidone
  • Indications Idiopathic pulmonary fibrosis
  • Focus Therapeutic Use
  • Acronyms GALACTIC-1
  • Sponsors Galecto Biotech
  • Most Recent Events

    • 05 Feb 2019 Status changed from planning to not yet recruiting.
    • 01 Nov 2018 New trial record
    • 26 Oct 2018 According to a Galecto Biotech media release, the company has received the finance to conduct this study for the investors. The study design is agreed by the FDA and MHRA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top